positions this year, including top research and development talent as we Argus® II Terry and Sue’s Story . Potential Drive Refined Strategy --, -- Company to Provide Continued Support for Existing Argus® But an adverse safety signal is more of a concern, and sent the company’s shares down 9% … Section 21E of the Securities Exchange Act of 1934, as amended, which Thinly traded micro cap Second Sight Medical Products (NASDAQ:EYES) slips 11% premarket on increased volume in reaction to its update on its early feasibility study of the Orion … The Orion® System is an implanted cortical stimulation device that leverages Second Sight’s 20+ years of experience in neuromodulation for vision. that Orion offers the most effective and quickest path forward to treat The phenomenon of ‘second sight’ is quite interesting as it appears to the patients to be a ‘magical’ restoration of vision after the vision of the patient becomes poor. With encouraging early clinical results, we believe now is the right time for the Company to transition to the Orion platform and focus on accelerating our development and clinical programs. Forward-looking Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or reports filed from time to time with the Securities and Exchange Accordingly, we will suspend production of new Argus II systems in the “To support these initiatives, we intend to add more than 25 new positions this year, including top research and development talent as we pursue technological improvements of Orion. We are also taking steps to further align our organizational capabilities and focus resources primarily on advancing Orion as well as prepare for future sales volumes that we expect to be orders of magnitude greater than Argus II. View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005890/en/. Gregg Williams, Chairman of the Board, added, “Orion provides a tremendous opportunity to further advance the field of artificial vision while also addressing the needs of millions of blind individuals globally. „Bei manchen Arten von Blindheit ist der Sehnerv beschädigt, so dass man tiefer ansetzen muss. It is intended to provide useful artificial vision to individuals who are blind due to a range of causes including eye injury, glaucoma, diabetic retinopathy, and optic nerve injury or disease. This press release contains forward-looking statements within the Second Sight called the first-in-human implant of the Orion a significant milestone, and a critical step forward in its development of devices that it believes could potentially treat nearly all forms of blindness. eye anatomy and to transmit these electrical pulses wirelessly to an The “O” in the logo represents the single-hole cannulated stock used in surgical instruments and implants. It also offers biocompatibility with a simple preparation and application process for surgeons. Company is committed to developing new technologies to treat the Mit den Tests über das Orion-System will Second Sight herausfinden, ob ein Elektroden-Array auf der Oberfläche des Gehirns Menschen helfen kann, die teilweise oder vollkommen blind geworden sind. Photo: Courtesy of Aline Berry/Pixabay. primarily on advancing Orion as well as prepare for future sales volumes statement contained herein (or elsewhere) to reflect any change in our Cortical Prosthesis System (“Orion”). The vascular sealant is designed to quickly achieve hemostasis and prevent post-operative bleeding after peripheral vascular surgeries. The “A Team’s” Argus® II Story. The new system is designed with six arms to provide more control and flexibility in surgery, while its arms will be integrated into the operating table. Prior to joining Minneapolis-based Diversified Plastics, Pope was president & CEO of… […], Forécreu — maker of hollow bars for the medical device market — has unveiled a new logo meant to feature a simple, bold, modern look. Charlotte’s Argus® II Story. “Company CEO Will McGuire said: “We believe it is the right time to reallocate resources toward this more attractive platform [Orion], which holds the potential to treat virtually all forms of blindness and extend our leadership position in artificial vision.”. “expects,” “intends,” “believes,” “should,” and similar expressions, or However, the Orion system transmits those signals directly to an array of electrodes implanted on the surface of a patient’s visual cortex – thus by-passing both the eye and the optic nerve, and the effects of diseases that have damaged them. the clinical and regulatory pathway to commercialization with the FDA as historical fact are “forward looking statements.” These statements may Management’s Discussion and Analysis of Financial Condition and Results Like its predecessor products, Orion converts images captured by a miniature video or thermal camera mounted on glasses into electrical signals that can be perceived by the brain to form images. For further information on how we use cookies, please read our Privacy Policy. We remain encouraged by our discussions with the U.S. Food and Drug Administration (FDA) regarding Orion’s regulatory path and are pleased by recent developments with the Centers for Medicare and Medicaid Services (CMS) regarding reimbursement for products approved via the FDA’s Breakthrough Devices program.”. “And we now believe [that] Orion offers the best and fastest path to do so.”. We are also taking steps to Laut Robert Greenberg, dem Board-Vorsitzenden von Second Sight, wurden bislang erst etwa 250 Exemplare von Argus II verkauft, weniger als von ihm erwartet. Communications, Inc.Lisa Wilson, PresidentT: 212-452-2793E: federal securities laws, we disclaim any obligation or undertaking to No peer-reviewed data is Wenn das Konzept von Second Sight funktioniert, könnten Millionen von Blinden in der ganzen Welt … List of the stories. Argus II arbeitet mit einer auf einer Brille befestigten Kamera. Sight. Diese Zellen können die visuellen Informationen über den Sehnerv an das Gehirn leiten. Photo: Courtesy of Aline Berry/Pixabay. 949-385-6449E: greg.falesnik@mzgroup.us, Media:Nobles Global CommunicationsLaura Nobles or The company says that will be enough to sustain operations for around another 12 months, by which time it is hoped that discussions with US health authorities regarding payment reimbursements will have progressed significantly. Argus® II Lisa’s Story. Wenn das Konzept von Second Sight funktioniert, könnten Millionen von Blinden in der ganzen Welt profitieren, auch solche, die ein Auge oder beide Augen verloren haben. Helen ShikT: 617-510-4373E: Laura@noblesgc.comE: additional feasibility subjects in 2019 while simultaneously negotiating The “A Team’s” Argus® II Story. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media. The sixth patient in the early-stage study, who received the Orion implant in January, has recently been cleared to return home, and is said to be doing well. our continued investment in multiple research projects designed to Read on to find out more about the 10 largest companies in the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medical device… […], SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, InvestorsMZ North AmericaGreg Falesnik, Managing DirectorT: Diese so genannten bionischen Augen sind dazu gedacht, Patienten mit einer genetischen Augenerkrankung namens Retinitis pigmentosa ein gewisses Sehvermögen zurückzugeben. visual prosthetics that are intended to create an artificial form of LOS ANGELES--(BUSINESS WIRE)--May 15, 2019-- disease or injury, and retinitis pigmentosa (“RP”). Source: Second Sight Medical Products, Inc. Investor Relations:Institutional InvestorsIn-Site including glaucoma, eye injury, diabetic retinopathy, optic nerve Placement of the Implantable Device on the Visual Cortex, Scientific breakthrough may eventually allow many blind people to see, Baylor College of Medicine helping blind people see again, Novel Brain Implant Restores Visual Perception to the Blind, 20+ years of experience in neuromodulation for vision.